Business
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
Increase in stockholder equity and note extension strengthen Company’s ability to advance pancreatic cancer development strategyOCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to its existing promissory note agreement with Streeterville Capital, LLC, extending the maturity date to June 30, 2027. AIM recently reported stock
About this update from Aim Immunotech Inc.
[{"type":"image","alt":"AIM ImmunoTech Inc.","displaySize":"","headline":null,"caption":"AIM ImmunoTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KYO5lLNJMwtczbtJGn_KoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNA--/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/KYO5lLNJMwtczbtJGn_KoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNA--/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160}},"lazy":false},{"type":"text","content":"Increase in stockholder equity and note extension strengthen Company’s ability to advance pancreatic cancer development strategy","length":128,"tagName":"p"},{"type":"text","content":"OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to its existing promissory note agreement with Streeterville Capital, LLC, extending the maturity date to June 30, 2027.","length":349,"tagName":"p"},{"type":"text","content":"AIM recently reported stockholder equity of approximately $2.1 million as of March 31, 2026, which is a significant increase of approximately $11.9 million in stockholder equity from the reported stockholder deficit of approximately $9.8 million as of December 31, 2025. The Company has also raised equity-generating funds through various transactions since March 31, 2026.","length":373,"tagName":"p"},{"type":"text","content":"The Company believes the increase in stockholder equity and the note extension further support its ability to prudently manage capital resources while maintaining focus on near-term milestones, including continued advancement of its pancreatic cancer development program and other strategic initiatives intended to maximize long-term stockholder value.","length":352,"tagName":"p"},{"type":"text","content":"“We appreciate the continued support and confidence demonstrated by Streeterville Capital through this extension,” said AIM Chief Executive Officer Thomas Equels. “This amendment enhances our capit...